Implementation of a Traceback Testing Program for Ovarian Cancer: Findings from the FACTS Study.
Publication Title
Cancers (Basel)
Document Type
Article
Publication Date
3-29-2025
Keywords
cancer prevention; gynecologic cancer risk reduction; ovarian cancer.
Abstract
Background: Traceback testing-identifying and offering testing to people with previous cancer diagnoses who have not received current standard genetic testing-could benefit patients and their at-risk relatives.
Methods: We conducted a multisite, nonrandomized pilot implementation study of a Traceback program at three integrated United States health systems. We assessed the reach, fidelity, effectiveness, and acceptability of the program using quantitative and qualitative methods.
Results: We identified 597 eligible individuals using administrative data and manual chart review. We attempted to reach everyone identified (100% fidelity). We successfully contacted 354 people, for a reach of 59% of confirmed eligible individuals. In total, 133 people completed Traceback genetic testing. Ten of these (8%) received pathogenic or likely pathogenic results;. Nine of these ten people received positive results for which cascade testing of at-risk relatives would be indicated. None of their relatives underwent cascade testing during the study period. Thirty-six received variants of uncertain significance (VUS). Traceback programs were acceptable to participants and implementers and thought to be applicable to other genetic screening conditions. The time and resources required to accurately identify Traceback-eligible individuals are likely determinants of future sustainability.
Conclusions: Education about free cascade testing, reminder calls to probands, and offers to directly contact at-risk relatives did not result in cascade testing in this pilot study. However, participant and implementer discussions suggest that the potential benefits of Traceback programs and high participant acceptability are worthy of further study.
Area of Special Interest
Women & Children
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Oncology
DOI
10.3390/cancers17071154
